20.32
0.58 (2.94%)
| Penutupan Terdahulu | 19.74 |
| Buka | 19.77 |
| Jumlah Dagangan | 2,330,166 |
| Purata Dagangan (3B) | 2,705,780 |
| Modal Pasaran | 1,766,109,568 |
| Harga / Jualan (P/S) | 14.61 |
| Harga / Buku (P/B) | 14.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Nov 2025 |
| Margin Operasi (TTM) | -416.67% |
| EPS Cair (TTM) | -3.85 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 160.71% |
| Nisbah Semasa (MRQ) | 5.80 |
| Aliran Tunai Operasi (OCF TTM) | -286.52 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -169.65 M |
| Pulangan Atas Aset (ROA TTM) | -36.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Syndax Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.20 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.29% |
| % Dimiliki oleh Institusi | 120.71% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 56.00 (BTIG, 175.59%) | Beli |
| Median | 39.00 (91.93%) | |
| Rendah | 33.00 (JP Morgan, 62.40%) | Beli |
| Purata | 41.00 (101.77%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 15.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 24 Nov 2025 | 35.00 (72.24%) | Beli | 19.76 |
| 04 Nov 2025 | 22.00 (8.27%) | Beli | 15.35 | |
| JP Morgan | 12 Nov 2025 | 33.00 (62.40%) | Beli | 16.79 |
| UBS | 04 Nov 2025 | 38.00 (87.01%) | Beli | 15.35 |
| BTIG | 27 Oct 2025 | 56.00 (175.59%) | Beli | 13.11 |
| 19 Sep 2025 | 56.00 (175.59%) | Beli | 14.78 | |
| HC Wainwright & Co. | 27 Oct 2025 | 40.00 (96.85%) | Beli | 13.11 |
| 16 Oct 2025 | 40.00 (96.85%) | Beli | 15.05 | |
| Stifel | 10 Sep 2025 | 44.00 (116.54%) | Beli | 15.73 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GOLDAN KEITH A. | - | 19.12 | -1,224 | -23,403 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,224 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -23,403 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 19.12 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GOLDAN KEITH A. | Pegawai | 01 Dec 2025 | Dibuang (-) | 1,224 | 19.12 | 23,403 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |